MYHIBBIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Myhibbin, and what generic alternatives are available?
Myhibbin is a drug marketed by Azurity and is included in one NDA. There are three patents protecting this drug.
This drug has four patent family members in three countries.
The generic ingredient in MYHIBBIN is mycophenolate mofetil. There are thirty-eight drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the mycophenolate mofetil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Myhibbin
A generic version of MYHIBBIN was approved as mycophenolate mofetil by HIKMA on July 29th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MYHIBBIN?
- What are the global sales for MYHIBBIN?
- What is Average Wholesale Price for MYHIBBIN?
Summary for MYHIBBIN
| International Patents: | 4 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 4,341 |
| What excipients (inactive ingredients) are in MYHIBBIN? | MYHIBBIN excipients list |
| DailyMed Link: | MYHIBBIN at DailyMed |
Pharmacology for MYHIBBIN
| Drug Class | Antimetabolite Immunosuppressant |
US Patents and Regulatory Information for MYHIBBIN
MYHIBBIN is protected by three US patents.
Patents protecting MYHIBBIN
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PROPHYLAXIS OF ORGAN REJECTION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PROPHYLAXIS OF ORGAN REJECTION
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | MYHIBBIN | mycophenolate mofetil | SUSPENSION;ORAL | 216482-001 | May 1, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Azurity | MYHIBBIN | mycophenolate mofetil | SUSPENSION;ORAL | 216482-001 | May 1, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Azurity | MYHIBBIN | mycophenolate mofetil | SUSPENSION;ORAL | 216482-001 | May 1, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MYHIBBIN
See the table below for patents covering MYHIBBIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 3836898 | SUSPENSION PHARMACEUTIQUE POUR FORME GALÉNIQUE ORALE (PHARMACEUTICAL SUSPENSION FOR ORAL DOSAGE) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2020039263 | ⤷ Sign Up | |
| United Kingdom | 2591396 | Pharmaceutical suspension for oral dosage | ⤷ Sign Up |
| United Kingdom | 202103764 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MYHIBBIN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0281713 | SPC/GB96/026 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MYCOPHENOLATE MOFETIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 53337 19951103; CH 53338 19951103; UK EU/1/96/005/001 19960214; UK EU/96/005/002 19960214 |
| 0281713 | 96C0031 | Belgium | ⤷ Sign Up | PRODUCT NAME: MYCOPHENOLATE MOFETIL; NAT. REGISTRATION NO/DATE: EU/1/96/005/001 19960214; FIRST REGISTRATION: CH 53337 19951103 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
